Lipids and Lipoprotein Abnormalities

Classification of Clinical Lipoprotein Disorders

  • Diagnosis of dyslipoproteinemia mainly involves the evaluation of serum/plasma lipid and lipoprotein levels.

  • Hyperlipidemia: An elevation of lipoprotein concentration classified by:

    • Identification of specific elevated lipoproteins.

    • Exploring secondary causes before identifying primary disorders (genetic or environmental).

A. Hyperlipidemia

  • Elevated lipoproteins due to genetic abnormalities or secondary causes from diseases.

  • Includes common and rare genetic disorders affecting enzyme activity or receptor functions.

B. Arteriosclerosis

  • Leading cause of death/disability, connected to lipid deposition in arteries (atherosclerosis).

  • Involves gradual thickening of arterial walls, decreased elasticity, and halting blood flow, causing ischemia.

  • Risk factors for atherosclerosis:

    • Age (45 for men, 55 for women)

    • Male gender, hypertension, smoking, diabetes mellitus, and family history.

C. Atherosclerosis Development

  • Begins with fatty streaks (excess fat in macrophages) rising to plaque formations that block flow.

  • Key terms:

    • LDL: Plays a central role in plaque formation.

    • Thrombus: Can rupture plaques, leading to heart attacks (MI).

II. Lipid Abnormalities

  • Lipids (cholesterol, triglycerides) serve as indicators for hormonal and metabolic issues.

  • Hormonal influences on cholesterol levels:

    • Thyroid hormone: Hypothyroidism raises cholesterol levels.

    • Insulin: Low levels correlate with raised cholesterol—typical in diabetes.

    • Estrogens: Higher levels generally associate with lower cholesterol.

III. Types of Hyperlipoproteinemias

  1. Familial Chylomicronemia: LPL deficiency leads to elevated triglycerides and chylomicrons without coronary heart disease risk.

  2. Familial Hypercholesterolemia: Cause LDL's failure to clear, boosting levels significantly, high CHD risk.

  3. Combined Hyperlipoproteinemia: Elevated cholesterol and triglycerides, increased CHD risk.

  4. Familial Dysbetalipoproteinemia: Faulty IDL/chylomicron remnants removal; diagnosed via apo E isoform.

  5. Familial Hypertriglyceridemia: Common, often secondary to hormonal imbalances, risk for pancreatitis.

  6. Lipoprotein (a) Excess: Increased CHD risk alongside elevated LDL.

  7. Familial Hyperalphalipoproteinemia: High HDL levels, often asymptomatic but can aid in cardioprotection.

IV. Lipid Changes After Myocardial Infarction

  • Post-MI lipid changes commence after 24 hours, with cholesterol decreasing, reaching a low in 4-6 days.

  • Triglycerides show a mild rise, peaking 3-5 weeks post-event.

V. Hypolipoproteinemia

  • Rare congenital disorders causing deficiencies in lipoproteins:

    • Abetalipoproteinemia: Associated with vitamin malabsorption and neurological degeneration.

    • Hypobetalipoproteinemia: Usually asymptomatic, leads to lower coronary disease risk.

    • Analphalipoproteinemia (Tangier Disease): Characterized by very low HDL levels, potential cardiovascular risks.

    • Hypoalphalipoproteinemia: Generally associated with slight cardiovascular risks due to decreased HDL.

VI. Diagnosis of Lipoprotein Disorders

  • Comprises testing total cholesterol, triglycerides, HDL, and LDL levels.

  • Risk assessment incorporates medical history and presence of known risk factors.

Key Takeaways

  • Lipid abnormalities often signal underlying hormonal or metabolic issues, crucial for understanding disease implications.

  • Measurement of lipid profiles reveals vital information about cardiovascular risk and needs for preventive or therapeutic interventions.

Note

  • Utilization of LDL/HDL cholesterol ratio for determining coronary artery disease risk is important due to variabilities in single lipid measurements.

Cholesterol Levels by Age and Sex

  • Normal variations should be considered in context; age and gender impact lipid profiles significantly.